Keywords: Ipsen, Debipharm, Decapeptyl, prostate cancer, Recordati, silodosin, Prostatic hyperplasia

Ipsen debuts Decapeptyl in France, Recordati gains EU clearance for silodosin

Article | 4 February 2010

French specialty drugmaker Ipsen and Swiss biopharmaceutical group Debiopharm have announced the launch by Ipsen in France of Decapeptyl (triptorelin embonate1) LP 22.5mg six-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal.

The marketing authorization (MA) to this formulation of Decapeptyl was granted on November 10, 2009, by the French regulatory authority (Agence Française de Securite Sanitaire des Produits de Sante, AFSSAPS) for the treatment of locally advanced and metastatic hormone-dependent prostate cancer. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in